Insmed, Inc.
INSMInsmed, Inc. is a global biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare and serious diseases. Founded in 2013 and headquartered in Bridgewater, New Jersey, Insmed primarily specializes in treatments for rare pulmonary conditions, including nontuberculous mycobacterial lung disease and other orphan diseases. The company’s leading product is Arikayce (liposomal amikacin), approved for treating bacterial lung infections. Insmed emphasizes research and development to bring novel solutions to underserved patient populations.
Company News
Alumis shares surged 94.53% following positive Phase 3 trial results for envudeucitinib, an oral TYK2 inhibitor for psoriasis that met primary and secondary endpoints. The company announced plans to raise $175 million in capital to support commercialization of the drug and its pipeline. The broader market rose modestly with the S&P 500 gaining 0....
Ten large-cap stocks experienced significant declines last week. Nike fell 12.81% due to a 17% decline in Greater China sales and analyst downgrades. ARM Holdings dropped 9.77% following Goldman Sachs and Bank of America downgrades. Other major losers included Lennar (9.94% decline after earnings miss), Marathon Petroleum (9.42%), Phillips 66 (8....
Nasdaq announced its annual Nasdaq-100 Index reconstitution, adding six companies and removing six others, effective December 22, 2025. The changes reflect the dynamic composition of leading non-financial companies across various sectors.
Billionaire investor Stanley Druckenmiller has invested 30% of his portfolio in three biotech stocks: Natera, Insmed, and Teva Pharmaceutical Industries, demonstrating strong confidence in the biotech sector's potential.
The DPP1 inhibitor market is experiencing significant growth, driven by BRINSUPRI's approval for non-cystic fibrosis bronchiectasis and increasing prevalence of respiratory diseases. Multiple emerging therapies are advancing in clinical trials, with potential to transform treatment landscapes.
